152 related articles for article (PubMed ID: 37034380)
1. Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report.
Lu TJ; Amarikwa L; Winn BJ; Inserra M; Dosiou C; Kossler AL
Case Rep Ophthalmol; 2023; 14(1):134-139. PubMed ID: 37034380
[TBL] [Abstract][Full Text] [Related]
2. Ototoxicity and Teprotumumab.
Highland J; Gordon S; Reddy D; Patel N
Ann Otol Rhinol Laryngol; 2022 Aug; 131(8):910-913. PubMed ID: 34448414
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab-associated chronic hearing loss screening and proposed treatments.
Chow A; Silkiss RZ
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418378
[TBL] [Abstract][Full Text] [Related]
4. Audiology findings in patients with teprotumumab associated otologic symptoms.
Yu CY; Correa T; Simmons BA; Hansen MR; Shriver EM
Am J Ophthalmol Case Rep; 2021 Dec; 24():101202. PubMed ID: 34585021
[TBL] [Abstract][Full Text] [Related]
5. Sensorineural Hearing Loss After Teprotumumab Therapy for Thyroid Eye Disease: A Case Report.
Ding AS; Mahoney NR; Campbell AA; Creighton FX
Otol Neurotol; 2022 Feb; 43(2):e148-e152. PubMed ID: 34789694
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring.
Belinsky I; Creighton FX; Mahoney N; Petris CK; Callahan AB; Campbell AA; Kazim M; Lee HBH; Yoon MK; Dagi Glass LR
Ophthalmic Plast Reconstr Surg; 2022 Jan-Feb 01; 38(1):73-78. PubMed ID: 34085994
[TBL] [Abstract][Full Text] [Related]
7. Frequency and Patterns of Hearing Dysfunction in Patients Treated with Teprotumumab.
Keen JA; Correa T; Pham C; Claussen AD; Hansen MR; Carter KD; Shriver EM
Ophthalmology; 2024 Jan; 131(1):30-36. PubMed ID: 37567417
[TBL] [Abstract][Full Text] [Related]
8. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease.
Sears CM; Azad AD; Amarikwa L; Pham BH; Men CJ; Kaplan DN; Liu J; Hoffman AR; Swanson A; Alyono J; Lee JY; Dosiou C; Kossler AL
Am J Ophthalmol; 2022 Aug; 240():1-13. PubMed ID: 35227694
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy.
Phansalkar R; Lu T; Alyono J; Lee J; Dosiou C; Kossler AL
Ophthalmic Plast Reconstr Surg; 2023 Jul-Aug 01; 39(4):e101-e104. PubMed ID: 36877549
[TBL] [Abstract][Full Text] [Related]
10. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease.
Safo MB; Silkiss RZ
Am J Ophthalmol Case Rep; 2021 Jun; 22():101069. PubMed ID: 33817409
[TBL] [Abstract][Full Text] [Related]
11. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
12. Clinical Practice Guideline: Sudden Hearing Loss (Update).
Chandrasekhar SS; Tsai Do BS; Schwartz SR; Bontempo LJ; Faucett EA; Finestone SA; Hollingsworth DB; Kelley DM; Kmucha ST; Moonis G; Poling GL; Roberts JK; Stachler RJ; Zeitler DM; Corrigan MD; Nnacheta LC; Satterfield L
Otolaryngol Head Neck Surg; 2019 Aug; 161(1_suppl):S1-S45. PubMed ID: 31369359
[TBL] [Abstract][Full Text] [Related]
13. Clinical Practice Guideline: Sudden Hearing Loss (Update) Executive Summary.
Chandrasekhar SS; Tsai Do BS; Schwartz SR; Bontempo LJ; Faucett EA; Finestone SA; Hollingsworth DB; Kelley DM; Kmucha ST; Moonis G; Poling GL; Roberts JK; Stachler RJ; Zeitler DM; Corrigan MD; Nnacheta LC; Satterfield L; Monjur TM
Otolaryngol Head Neck Surg; 2019 Aug; 161(2):195-210. PubMed ID: 31369349
[TBL] [Abstract][Full Text] [Related]
14. Teprotumumab: A Review in Thyroid Eye Disease.
Nie T; Lamb YN
Drugs; 2022 Nov; 82(17):1663-1670. PubMed ID: 36418673
[TBL] [Abstract][Full Text] [Related]
15. Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion.
Kelly DA; Turbin RE
Am J Ophthalmol Case Rep; 2024 Jun; 34():102031. PubMed ID: 38487336
[TBL] [Abstract][Full Text] [Related]
16. Thyroid Eye Disease, Teprotumumab, and Hearing Loss: An Evolving Role for Otolaryngologists.
Chern A; Dagi Glass LR; Gudis DA
Otolaryngol Head Neck Surg; 2021 Dec; 165(6):757-758. PubMed ID: 33781112
[TBL] [Abstract][Full Text] [Related]
17. A Novel Case of Hyperglycemic Hyperosmolar State After the Use of Teprotumumab in a Patient With Thyroid Eye Disease.
Shah K; Charitou M
AACE Clin Case Rep; 2022; 8(4):148-149. PubMed ID: 35959086
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab in advanced reactivated thyroid eye disease.
Cheng OT; Schlachter DM
Am J Ophthalmol Case Rep; 2022 Jun; 26():101484. PubMed ID: 35321251
[TBL] [Abstract][Full Text] [Related]
19. Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series.
Chu M; Sung J; Song M; Song A; Song J
J Med Case Rep; 2022 May; 16(1):195. PubMed ID: 35538553
[TBL] [Abstract][Full Text] [Related]
20. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.
Hoang TD; Nguyen NT; Chou E; Shakir MK
BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 33972303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
